Ventripoint Diagnostics said this week it won CE Mark approval in the European Union for its VMS+ whole heart analysis system. The VMS+ system is designed to use conventional 2D ultrasound images to analyze the four chambers of the heart, the Toronto-based company said. Ventripoint touted the system as equivalent in accuracy to magnetic resonance imaging, […]
Ventripoint Diagnostics this week announced the publication of a study of its VMS heart analysis system, touting that the system’s functionality. The study, undertaken by the cardiology group at London’s Royal Free Hospital, was published in the journal Echocardiography. Results from the study indicate that the system was able to follow patients with enlarged right […]
Ventripoint Diagnostics said today it raised $600,000 in a new private placement of 4 million units, as its Chinese joint venture with Shanghai YuTian Medical Investment Management launched. The Canadian company said it floated the units at 15¢ apiece, with each consisting of 1 Ventripoint share and a 2-year, 1-share warrant redeemable at 30¢ per share, […]
Ventripoint said it pulled the trigger on a 1-for-10 reverse stock split, effective today. The move was approved by shareholders and the board at the company’s last annual general meeting. The company also received approval from the TSX Venture Exchange for the split, the company said. As a result of the split, every 10 shares of […]
Ventripoint said today it signed a deal with Chinese firm Shanghai YuTian Medical Investment, also known as Ventrisound, to sell 9.1 million units of stock for 5.5¢ per share, bringing in $500,000 with a possible extra $2.25 million upon reaching certain milestones. Each unit in the deal will consist of 1 common share of Ventripoint […]
AdvaMed said it named Shaye Mandle, CEO of Minnesota’s LifeScience Alley trade association, as chairman of its State Medical Technology Alliance. “The medical technology industry is a hallmark of U.S. innovation represented by a community of people dedicated to improving and saving lives. Now more than ever, medical technology has the opportunity to help deliver […]
Ventripoint Diagnostics assured investors that the company is inching ever closer to FDA submission of its Pulmonary Arterial Hypertension product, touting a recent $500,000 funding round.
Ventripoint had previously submitted an application for FDA consideration, and the agency asked the company to provide additional information on the PAH technology. In response the company prepared what it calls a "detailed statistical plan" to beef up submission materials for the federal watchdog agency.
Ventripoint Diagnostics got the green-light from European regulators to launch the NRV 2D ultrasound imaging application on its VMS right-heart analysis platform, which allows clinicians to assess heart imaging in patients with additional cardiac conditions.